Consolidated sales of global products
| |
FY2005 |
FY2006 |
FY2007 |
| Prograf |
145.9 |
175.4 |
203.0 |
| |
Sales by Astellas |
140.1 |
170.1 |
198.2 |
| |
|
Japan |
14.2 |
19.0 |
24.6 |
| |
|
North America |
74.5 |
88.0 |
97.2 |
| |
|
Europe |
43.4 |
52.7 |
65.3 |
| |
|
Asia |
7.8 |
10.3 |
11.0 |
| |
Exports to third parties (Europe) |
5.8 |
5.2 |
4.8 |
| Harnal |
137.8 |
127.0 |
122.4 |
| |
Sales by Astellas |
100.3 |
81.4 |
75.7 |
| |
|
Japan |
44.9 |
38.5 |
37.5 |
| |
|
Europe |
49.5 |
35.3 |
29.5 |
| |
|
|
Capsule |
36.1 |
18.8 |
12.3 |
| |
|
|
Ominic OCAS |
13.3 |
16.4 |
17.2 |
| |
|
Asia |
5.9 |
7.5 |
8.2 |
| |
Bulk and royalties (Europe) |
37.4 |
45.5 |
46.7 |
| Vesicare |
14.8 |
36.2 |
60.1 |
| |
|
Japan |
- |
6.2 |
13.5 |
| |
|
North America |
7.7 |
17.6 |
27.7 |
| |
|
Europe |
7.1 |
12.3 |
18.5 |
| |
|
Asia |
- |
0.0 |
0.3 |
| Funguard/Mycamine |
15.2 |
16.5 |
17.8 |
| |
|
Japan |
14.0 |
12.8 |
12.8 |
| |
|
North America |
1.2 |
3.5 |
4.7 |
| |
|
Asia |
- |
0.0 |
0.2 |
| Protopic |
14.4 |
14.7 |
16.4 |
| |
|
Japan |
2.6 |
2.6 |
2.7 |
| |
|
North America |
6.5 |
7.1 |
8.0 |
| |
|
Europe |
4.9 |
4.5 |
5.2 |
| |
|
Asia |
0.2 |
0.3 |
0.4 |
| (Note) Sales of products in Japan are shown in a gross sales basis. |
Consolidated Sales of Other Products
Local sales - Japan
| |
FY2005 |
FY2006 |
FY2007 |
| Lipitor |
91.5 |
94.7 |
97.7 |
| Gaster |
68.8 |
62.2 |
60.9 |
| Micardis |
37.3 |
50.3 |
62.6 |
| Cefzon |
18.4 |
14.7 |
14.5 |
| Myslee |
17.1 |
19.4 |
21.5 |
| Seroquel |
15.2 |
16.8 |
19.2 |
| Celecox (Launched in Jun, 2007) |
- |
- |
3.7 |
| Geninax (Launched in Oct, 2007) |
- |
- |
3.7 |
| (Note) Sales of products are shown in a gross sales basis. |
- North America
| |
FY2005 |
FY2006 |
FY2007 |
| Scan* |
35.3 |
37.1 |
37.6 |
Disclaimer for Share Price Feed
The past performance of the price of securities must not be relied on as a guide to their future performance. Astellas pharma inc. has not reviewed, is not responsible for, and accepts no liability in respect of, any information or opinion contained on any other website.
For more detail information, please refer to Cautionary Statement.
